Atorvastatin effect on systemic lupus erythematosus disease activity: A double-blind randomized clinical trial

Clinical Rheumatology

Volumn 33, Issue 9, 2014, Pages 1273-1278

  Fatemi, Alimohammad ^a   Moosavi, Mahdi ^a   Sayedbonakdar, Zahra ^a   Farajzadegan, Ziba ^b   Kazemi, Mehdi ^a   Smiley, Abbas ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Disease activity; Randomized controlled trial; Systemic lupus erythematosus

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PREDNISOLONE; ANTIRHEUMATIC AGENT; HEPTANOIC ACID DERIVATIVE; LIPID; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; BLOOD; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PYRROLES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84906790536     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2654-7     Document Type: Article

References (31)

1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690-1697
2. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH (2009) Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 61(10):1396-1402
3. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303-1307 (Pubitemid 36314415)
4. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42(2):338-346
5. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial (2002). Lancet 360 (9326):7-22.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301-1307
7. Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868-874
8. Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109(21 Suppl 1):II18-II26 (Pubitemid 38724152)
9. Abeles AM, Pillinger MH (2006) Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 54(2):393-407 (Pubitemid 43228614)
10. Meroni PL, Luzzana C, Ventura D (2002) Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol 23(3):263-277 (Pubitemid 35178815)
11. Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 177(10):7416-7422 (Pubitemid 44715112)
12. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015-2021 (Pubitemid 38781100)
13. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363(9421):1607-1608 (Pubitemid 38625664)
14. Jury EC, Ehrenstein MR (2005) Statins: immunomodulators for autoimmune rheumatic disease? Lupus 14(3):192-196 (Pubitemid 40445582)
15. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR (2004) Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 173(12):7641-7646 (Pubitemid 39628206)
16. Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP (2008) Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum 58(7):2098-2104 (Pubitemid 351988101)
17. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12(8):607-611 (Pubitemid 37021796)
18. de Kruif MD, Limper M, Hansen HR, de Ruiter J, Spek CA, van Gorp EC, ten Berge IJ, Rowshani AT, ten Cate H, Meesters EW (2009) Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis 68(10):1654
19. Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, Karlson EW (2007) A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 27(11):1071-1077 (Pubitemid 47246586)
20. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS (2011) Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 70(5):760-765
21. Iranian Registry of Clinical Trials (2012) Comparison the efficacy of atorvastatin with placebo on disease activity in patients with systemic lupus erythematosus. http://www.irct.ir/.
22. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725
23. Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288-291 (Pubitemid 34118775)
24. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46(10):1560-1565 (Pubitemid 47500570)
25. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344(26):1959-1965 (Pubitemid 32568149)
26. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100(3):230-235 (Pubitemid 29340127)
27. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286(1):64-70 (Pubitemid 32606333)
28. Ridker PM, Rifai N, Lowenthal SP (2001) Rapid reduction in Creactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103(9):1191-1193 (Pubitemid 32221338)
29. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195-2207
30. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6(12):1399-1402 (Pubitemid 32001026)
31. Bianchi S, Bigazzi R, Caiazza A, Campese VM (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41(3):565-570 (Pubitemid 36278373)